Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/pibrentasvir in pediatric chronic hepatitis C
2016-004102-34Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glecaprevir and pibrentasvir in chronic hepatitis C (CHC), sponsored by AbbVie Inc. Primary endpoints: Steady-state AUC of ABT-493 and ABT-530, Pharmacokinetics of ABT-493/ABT-530 and 1 more. Started Jun 2017; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-004102-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004102-34.